Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination With Mirikizumab for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis

NCT06598943 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06598943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06598943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination With Mirikizumab for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 10, 2024
Completion date
July 31, 2027
Enrollment
143 (estimated)
Sites
207

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis, ulcerative colitis chronic